Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Kiromic Biopharma, Inc. (KRBP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement by and between Kiromic Biopharma, Inc. and Brian Hungerford"
10/02/2023 8-K Quarterly results
09/26/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/27/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of the 25% Senior Secured Convertible Promissory Note"
07/25/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
07/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/18/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
06/29/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/16/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/25/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/19/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/15/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Other Events  Interactive Data
04/28/2023 8-K Quarterly results
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/17/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "KIROMIC BIOPHARMA, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE",
"EXCHANGE AGREEMENT",
"KIROMIC BIOPHARMA, INC. 25% SENIOR SECURED CONVERTIBLE PROMISSORY NOTE AND SECURITY AGREEMENT"
03/31/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/10/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT to the FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of KIROMIC BIOPHARMA, INC.",
"Kiromic BioPharma Announces Reverse Stock Split HOUSTON – Kiromic BioPharma, Inc. , a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 effective as of 4:01 p.m. Eastern Time today, March 10, 2023. Kiromic common stock will begin trading on a split-adjusted basis when the market opens on March 13, 2023 under the existing trading symbol KRBP. As a result of the reverse stock split, the CUSIP number for the Company’ s common stock will now be 497634204. The reverse stock split was previously approved by Kiromic stockholders at the Spec..."
03/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/27/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "KIROMIC BIOPHARMA, INC. 25% SENIOR SECURED CONVERTIBLE PROMISSORY NOTE AND SECURITY AGREEMENT"
02/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/26/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "NOTE PURCHASE AGREEMENT",
"."
01/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
01/12/2023 SC 13G Empery Asset Management, LP reports a 10% stake in Kiromic Biopharma, Inc.
01/04/2023 SC 13G SABBY MANAGEMENT, LLC reports a 10% stake in Kiromic BioPharma, Inc.
12/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy